NCT06762769View on ClinicalTrials.gov

Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

June 2, 2025

Primary Completion Date

November 30, 2032

Study Completion Date

November 30, 2032

Conditions
Smouldering Myeloma
Interventions
DRUG

Isatuximab

Subcutaneous isatuximab will be delivered using an unlicensed medical device (On Body Delivery System)

DRUG

Iberdomide

Oral iberdomide

DRUG

Dexamethasone

Oral dexamethasone

Trial Locations (2)

EC1A 7BE

RECRUITING

Barts Health Trust, London

NG5 1PB

RECRUITING

Nottingham City Hospital, Nottingham

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Bristol Myers Squibb Pharmaceuticals Limited

UNKNOWN

lead

University College, London

OTHER

NCT06762769 - Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma | Biotech Hunter | Biotech Hunter